Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

Eli Lilly hiked its outlook as sales soared for its popular weight-loss drugs Zepbound and Mounjaro.  The company also recently announced a partnership with Walmart that will expand access to Zepbound ...

A new drug-sales king has been crowned. Eli Lilly’s diabetes and weight-loss drug tirzepatide, marketed under the Mounjaro ...

A $1 million Central Indiana Food Relief Fund has been launched to address the upcoming cuts to federal SNAP benefits due to ...

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...

Discover Eli Lilly’s Q3 2025 earnings highlights: record 54% revenue growth, new product approvals, raised guidance, and global expansion.

In parallel with mazisotine’s shelving, Lilly added a phase 1 NaV1.8 inhibitor from its SiteOne Therapeutics acquisition to ...

A new oral medication, Orforglipron, is set to revolutionize weight loss and diabetes management, offering a pill alternative ...

Danish pharmaceutical giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced Thursday an unsolicited ...

Eli Lilly’s Q3 2025 revenue jumped 54% to $17.6 billion with adjusted EPS of $7.02, prompting the company to lift its ...